Patent ID: 11957666
Assignee: VELOXIS PHARMACEUTICALS, INC.
Field: Pharmaceuticals (Chemistry)
Classification: CPC A | IPC A

Claim 11:
12. A method of suppressing organ rejection in a de novo African-American organ transplant recipient, the method comprising
(a) initiating oral treatment with a once-daily extended release tacrolimus dosage form at an initial dose of from about 0.15 to about 0.20 mg/kg/day following transplantation, wherein
(i) the once-daily extended release tacrolimus formulation provides a fluctuation of less than 100%, a swing less than 120% or both; and
(ii) the once-daily extended release tacrolimus formulation releases the tacrolimus substantially in the colon and/or the lower ileum; and

(b) concomitantly treating the recipient with an IL-2 receptor antagonist and mycophenolate mofetil.